CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 120 enrolled
Drug / intervention
Magseed and Sentimagdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03020888
NCT03020888N/ACompleted

A Prospective, Open Label, Post Marketing Study of Magseed and Sentimag in Patients Undergoing Surgical Excision of a Breast Lesion That Requires Preoperative Radiographic Localization

Endomagnetics Inc·interventional·Posted Jan 13, 2017·Updated Feb 4, 2021

In Brief

A clinical study evaluating Magseed and Sentimag for Disorders of Breast and Breast Lesions. Completed, enrolled 120 participants across 1 site.

Detailed Summary

The purpose of this post-marketing study is to provide prospective evidence that the Magseed and Sentimag® is effective for lesion localization in patients undergoing surgical excision of a breast lesion and to summarize measures of product safety and performance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJan 13, 2017
Enrollment StartJan 1, 2017
Primary CompletionFeb 1, 2018
Study CompletionJul 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.5 years ago

Interventions

Magseed and Sentimagdevice

Magseed marker and Sentimag probe for lesion localization